Positive ALDH1A3 and Negative GPX3 Expressions Are Biomarkers for Poor Prognosis of Gallbladder Cancer

Table 2

Relationship between ALDH1A3 and GPX3 expressions, clinicopathological characteristics, and average survival of SC/ASC and AC patients.

C.P characteristics	Samples (𝑛)	Average survival (month)	Chi-square	𝑃 value
SC/ASC
Differentiation
Well	16	13.81 (5–24)	19.125	0.000
Moderately	24	8.92 (4–18)
Poorly	6	5.83 (4–9)
Tumor mass size
≤3 cm	20	14.35 (7–24)	31.337	0.000
>3 cm	26	7.04 (4–11)
TNM stage
I + II	12	17.00 (9–24)	51.139	0.000
III	20	9.20 (7–15)
IV	14	5.86 (4–8)
Lymph node metastasis
No	17	14.24 (4–24)	16.219	0.000
Yes	29	7.86 (4–15)
Invasion
No	16	15.75 (9–24)	32.271	0.000
Yes	30	7.27 (4–12)
Surgery
Radical	14	16.64 (10–24)	50.165	0.000
Palliative	18	8.50 (6–12)
Biopsy	14	6.00 (4–8)
ALDH1A3
−	30	11.67 (6–24)	7.914	0.005
+	16	7.50 (4–15)
GPX3
−	27	8.00 (4–15)	9.917	0.002
+	19	13.69 (7–24)
AC
Differentiation
Well	27	15.07 (5–24)	32.501	0.000
Moderately	25	10.60 (4–24)
Poorly	28	6.68 (3–14)
Tumor mass size
≤3 cm	50	13.70 (6–24)	68.283	0.000
>3 cm	30	5.80 (3–10)
TNM stage
I + II	21	18.96 (5–24)	105.825	0.000
III	38	9.29 (6–15)
IV	21	5.14 (3–7)
Lymph node metastasis
No	30	16.27 (4–24)	42.372	0.000
Yes	50	7.42 (3–14)
Invasion
No	31	16.68 (7–24)	55.535	0.000
Yes	49	6.98 (3–11)
Surgery
Radical	26	18.31 (10–24)	113.141	0.000
Palliative	28	8.64 (6–11)
Biopsy	26	5.42 (3–9)
ALDH1A3
−	45	13.36 (6–24)	25.229	0.000
+	35	7.37 (3–18)
GPX3
−	42	7.05 (3–15)	40.507	0.000
+	38	14.82 (5–24)

C.P: clinicopathological.